Nε-(1-Carboxyethyl)-L-lysine (Synonyms: CEL) |
|
Katalog-Nr.GC45532
|
Nε-(1-Carboxyethyl)-L-lysine is an advanced glycation end product (AGE) formed by the reaction of methylglyoxal with lysine residues in proteins.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 5746-03-2
Sample solution is provided at 25 µL, 10mM.
Nε-(1-Carboxyethyl)-L-lysine is an advanced glycation end product (AGE) formed by the reaction of methylglyoxal with lysine residues in proteins[1-2]. Nε-(1-Carboxyethyl)-L-lysine can bind to the receptor for advanced glycation end products (RAGE) to influence cell signaling, modulating processes such as inflammatory responses, cell proliferation, and apoptosis. Nε-(1-Carboxyethyl)-L-lysine is applicable in research on aging, metabolism, and diabetes, as well as in the evaluation of Maillard reactions in food science[3-4].
In vitro, endothelial progenitor cells were treated with Nε-(1-Carboxyethyl)-L-lysine at concentrations ranging from 46ng/mL to 300μg/mL for 24-72 hours. Nε-(1-Carboxyethyl)-L-lysine downregulated the phosphorylation level of the MAPK signaling pathway and significantly inhibited the proliferation of endothelial progenitor cells, but Nε-(1-Carboxyethyl)-L-lysine had no significant effect on cell migration, tube formation ability, or apoptosis levels[5]. LO2 cells were treated with Nε-(1-Carboxyethyl)-L-lysine (10–50μM) for 24 hours. Nε-(1-Carboxyethyl)-L-lysine significantly upregulated the expression of RAGE and TET1 and promoted hypomethylation of the RAGE promoter[6].
In vivo, high-fat diet (HFD)-induced obese C57BL/6 mice were orally administered Nε-(1-Carboxyethyl)-L-lysine (7.5mg/kg/day) for 12 weeks. Nε-(1-Carboxyethyl)-L-lysine significantly reduced the mice body weight and simultaneously increased the accumulation level of Nε-(1-Carboxyethyl)-L-lysine in the liver[7].
References:
[1] Nemet I, Varga-Defterdarović L, Turk Z. Methylglyoxal in food and living organisms. Mol Nutr Food Res. 2006 Dec;50(12):1105-17.
[2] Oliveira AL, de Oliveira MG, Mónica FZ, et al. Methylglyoxal and Advanced Glycation End Products (AGEs): Targets for the Prevention and Treatment of Diabetes-Associated Bladder Dysfunction? Biomedicines. 2024 Apr 23;12(5):939.
[3] Hansen F, Battú CE, Dutra MF, et al. Methylglyoxal and carboxyethyllysine reduce glutamate uptake and S100B secretion in the hippocampus independently of RAGE activation. Amino Acids. 2016 Feb;48(2):375-85.
[4] Serrano JCE, Baena-Fustegueras JA, Martin-Gari M, et al. Adipose Tissue Protein Glycoxidation is Associated with Weight-Loss Potential. Obesity (Silver Spring). 2019 Jul;27(7):1133-1140.
[5] Zhu J, Yang K, Jing Y, et al. The effects of low-dose nepsilon-(carboxymethyl)lysine (CML) and nepsilon-(carboxyethyl)lysine (CEL), two main glycation free adducts considered as potential uremic toxins, on endothelial progenitor cell function. Cardiovasc Diabetol. 2012 Aug 1;11:90.
[6] Wu X, Shi X, Chen X, et al. Advanced glycation end products regulate the receptor of AGEs epigenetically. Front Cell Dev Biol. 2023 Feb 14;11:1062229.
[7] Huang SF, Chang YT, Hsia SM, et al. Distinct effects of methylglyoxal-derived hydroimidazolone 1, Nε-carboxyethyllysine, and an advanced glycation end product-rich diet on lipid metabolism, gut microbiota, and secondary bile acids in high-fat diet-induced obese mice. Food Chem. 2025 Nov 15;492(Pt 3):145634.
| Cell experiment [1]: | |
Cell lines | LO2 cells (human immortal non-tumor liver cell line) |
Preparation Method | LO2 cells were cultured in DMEM supplemented with 10% FBS and 1% antibiotics (streptomycin-penicillin) at 37°C, 5% CO₂. Cells were treated with Nε-(1-Carboxyethyl)-L-lysine (10–50μM) for 24h. |
Reaction Conditions | 10–50μM; 24h. |
Applications | Nε-(1-Carboxyethyl)-L-lysine dose-dependently increased the expression of the receptor for advanced glycation end products (RAGE) in LO2 cells. This upregulation was not completely blocked by inhibitors of the transcription factors NF-κB and STAT3. Nε-(1-Carboxyethyl)-L-lysine induced hypomethylation of the RAGE promoter region. This epigenetic effect was partially reversed using a dCAS9-DNMT3a system to target the RAGE promoter, which also partially blocked the Nε-(1-Carboxyethyl)-L-lysine -mediated increase in RAGE expression. Nε-(1-Carboxyethyl)-L-lysine treatment upregulated the expression of TET1, a DNA demethylase. |
| Animal experiment [2]: | |
Animal models | Male C57BL/6 mice with high-fat diet (HFD)-induced obesity |
Preparation Method | Four-week-old male C57BL/6 mice were fed a HFD (40% calories from fat) for 12 weeks. The mice received Nε-(1-Carboxyethyl)-L-lysine (7.5mg/kg/day) supplementation orally in addition to the HFD. All HFD-fed groups were provided with drinking water containing 10% fructose ad libitum. |
Dosage form | 7.5mg/kg/day; oral administration; 12 weeks. |
Applications | Chronic intracerebroventricular infusion of AC 253 improved spatial memory and learning deficits in aged TgCRND8 mice. AC 253 increased the expression of synaptic proteins synapsin 1 and synaptophysin, and significantly reduced the expression of the microglial marker Iba-1. |
References: | |
| Cas No. | 5746-03-2 | SDF | |
| Überlieferungen | CEL | ||
| Canonical SMILES | OC(C(NCCCC[C@H](N)C(O)=O)C)=O | ||
| Formula | C9H18N2O4 | M.Wt | 218.3 |
| Löslichkeit | Water: Slightly Soluble | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 4.5809 mL | 22.9043 mL | 45.8085 mL |
| 5 mM | 916.2 μL | 4.5809 mL | 9.1617 mL |
| 10 mM | 458.1 μL | 2.2904 mL | 4.5809 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >95.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 33 reference(s) in Google Scholar.)















